Reported risks and adverse effects associated with intravenous glutathione administration include the following: Injection site reactions: Bruising, pain, or swelling at the cannula insertion site are among the most commonly reported effects
Because of its higher level of safety and ease of use, long-acting basal insulin (a once daily injection), which has the ability to sustain insulin levels up to 24 hours, rather than a short-acting mealtime insulin injection, is preferred for patients who are insulin nave or at greater risk for hypoglycemia (Garber 2020)
In particular, several studies suggested that some anti-diabetic drugs could be of potential interest because of their anti-cancer effects demonstrated both in vitro and in vivo on TC
Throughout the trial, CagriSema, cagrilintide 2.4 mg, and semaglutide 2.4 mg demonstrated a safe and well-tolerated safety profile